Adaptive Biotechnologies’ shares rose over 10% following the National Comprehensive Cancer Network’s updated multiple myeloma guidelines recommending baseline clonotype identification at diagnosis or storage of bone marrow samples for minimal residual disease testing. This change from previous language is expected to increase uptake of Adaptive’s ClonoSeq assay by streamlining diagnostic workflows, particularly in community settings, thereby potentially driving recurrent testing volume growth.